ResMed (NYSE:RMD) Upgraded by StockNews.com to Buy Rating
StockNews.com upgraded shares of ResMed (NYSE:RMD – Free Report) from a hold rating to a buy rating in a report released on Saturday. Several other research analysts have also issued reports on RMD. KeyCorp upped their target price on ResMed from $266.00 to $280.00 and gave the company an “overweight” rating in a research report […]
StockNews.com upgraded shares of ResMed (NYSE:RMD – Free Report) from a hold rating to a buy rating in a report released on Saturday. Several other research analysts have also issued reports on RMD. KeyCorp upped their target price on ResMed from $266.00 to $280.00 and gave the company an “overweight” rating in a research report […]
